FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This clinical trial will determine whether the addition of radiotherapy to standard of care
systemic therapy improves objective progression-free survival compared to systemic therapy
alone in patients with oligometastatic castration-resistant prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center